Last reviewed · How we verify
NCT06948981
GT719 Injection for the Treatment of Recurrent/Refractory CD19 Positive Adult B-cell Malignancies
Phase 1, PHASE2 trial testing GT719 Injection in Hematological Malignancy (Leukemia- Lymphoma) in 46 participants. Currently enrolling.
17 April 2028
Quick facts
| Lead sponsor | Grit Biotechnology |
|---|---|
| Phase | Phase 1, PHASE2 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 46 |
| Start date | 18 April 2025 |
| Primary completion | 17 April 2028 |
| Estimated completion | 17 April 2028 |
| Sites | 1 location across China |
Drugs / interventions tested
- GT719 Injection — full drug profile →
Conditions studied
- Hematological Malignancy (Leukemia- Lymphoma) — all drugs for Hematological Malignancy (Leukemia- Lymphoma) →
Sponsor
Grit Biotechnology — full company profile →
Who can join
Adults 18 to 75, any sex, with Hematological Malignancy (Leukemia- Lymphoma). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study is a prospective single-arm open-labled phase I/II clinical trial, including dose escalation and expansion phase, aims to evaluate the safety, efficacy, and cellular pharmacokinetics of GT719 Injection in relapsed/refractory CD19 positive adult B-cell non Hodgkin lymphoma (B-NHL) and B-acute lymphoblastic leukemia (B-ALL) patients. A total of 46 subjects (anticipated) will be enrolled in this study.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06948981
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of GT719 Injection
Trials testing the same drug.
- NCT07122076 — GT719 Injection for Moderate to Severe Refractory Autoimmune Diseases · EARLY_PHASE1 · recruiting
- NCT07131254 — A Clinical Study Evaluating the Safety and Efficacy of GT719 Universal Cell Injection in Adult Participants With Relapse · EARLY_PHASE1 · recruiting
- NCT07021209 — GT719 Injection for Recurrent/Refractory Antibody-mediated Neurological Immune Diseases · Phase 1 · recruiting
Other recruiting trials for Hematological Malignancy (Leukemia- Lymphoma)
Currently open trials in the same condition.
- NCT07131254 — A Clinical Study Evaluating the Safety and Efficacy of GT719 Universal Cell Injection in Adult Participants With Relapse · EARLY_PHASE1 · recruiting
Other Grit Biotechnology trials
Trials by the same sponsor.
- NCT07534813 — A Single-Arm Clinical Study of Autologous Tumor-Infiltrating Lymphocyte Injection (GT307) in the Treatment of Metastatic · NA · not yet recruiting
- NCT07389499 — A Clinical Study Evaluating the Safety and Efficacy of GT719 Universal Cell Injection in the Treatment of Immune-mediate · EARLY_PHASE1 · recruiting
- NCT07253259 — A Clinical Study Evaluating the Safety and Efficacy of GT729 Universal Cell Injection in the Treatment of Refractory or · EARLY_PHASE1 · recruiting
- NCT07333118 — A Clinical Study to Evaluate the Safety and Efficacy of GT801 Injection in the Treatment of Moderate-to-Severe Refractor · EARLY_PHASE1 · recruiting
- NCT07205315 — A Clinical Study Evaluating the Safety and Efficacy of GT801 Injection in Adult Patients With Relapsed/Refractory CD19-p · EARLY_PHASE1 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06948981 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Grit Biotechnology
- Last refreshed: 16 September 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06948981.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing